Gilteritinib Production Cost Reports

The report provides a detailed analysis essential for establishing a Gilteritinib production plant. It encompasses all critical aspects necessary for Gilteritinib production, including the cost of Gilteritinib production, Gilteritinib plant cost, Gilteritinib production costs, and the overall Gilteritinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Gilteritinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Gilteritinib is a targeted pharmaceutical compound with applications mainly in the medical and healthcare sector. It is primarily used as an oral anticancer drug for the treatment of acute myeloid leukaemia (AML) in patients who have specific FLT3 gene mutations. It works by blocking abnormal signalling pathways that promote the growth and survival of cancer cells, which helps to control disease progression. It is mainly used in targeted therapy for patients with relapsed or treatment-resistant AML. It is taken as an oral tablet and is known to slow the progression of the disease and improve survival in some patients. It is often used in clinical research to study kinase inhibition, cancer resistance mechanisms, and the development of next-generation targeted therapies for blood-related cancers.

The primary factor that drives the market for Gilteritinib is its demand as a specialised anti-cancer medicine for the treatment of acute myeloid leukaemia in patients with FLT3 mutations. Its application as a part of targeted long-term treatment plans for relapsed or refractory leukaemia cases further fuels its demand in the oncology and medical sectors.

Its demand in the research and biotechnology industries to explore its use in combination with other drugs to increase its effectiveness in treating blood cancers also promotes its market expansion. Moreover, its role in treating relapsed or refractory leukaemia cases also adds to sustained demand from hospitals and cancer treatment centres. Factors such as the availability of high-quality intermediates, compliance with stringent regulatory standards for anti-cancer drugs, and adherence to safety and quality guidelines significantly influence industrial Gilteritinib procurement. In addition, advancements in drug production technologies, supplier reliability, patent considerations, and efficient global distribution systems play an important role in shaping procurement strategies and supporting the overall market expansion.

Raw Material for Gilteritinib Production

According to the Gilteritinib production plant project report, the major raw materials for Gilteritinib production include Chloropyrazine, Aminopyran, and Aniline.

Production Process of Gilteritinib

The extensive Gilteritinib production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of Gilteritinib begins with the reaction of chloropyrazine with an aminating reagent (aminopyran) in the presence of a suitable base to form an aminopyrazine intermediate. Then, this intermediate is coupled with an aniline fragment using a palladium-catalysed amination step, which adds the main aromatic subunit and builds the core framework of the molecule. The resulting intermediate contains a nitrile group, which is then converted to the corresponding carboxamide or carboxylic acid functionality through a controlled hydrolysis step. After completion of hydrolysis, the product mixture is worked up and purified to isolate Gilteritinib as the final active pharmaceutical ingredient.

Gilteritinib is a small-molecule tyrosine kinase inhibitor used in the treatment of acute myeloid leukaemia and functions by inhibiting FLT3 and AXL kinases. It appears as a white to off-white solid with no characteristic odour under normal conditions. The molecular formula of the compound is C29H44N8O3, and its molar mass is approximately 552.7 g/mol. The compound is practically insoluble in water but shows solubility in organic solvents such as dimethyl sulfoxide and methanol, reflecting its lipophilic character. The boiling point of the compound is 696 degree Celsius at 760 mm Hg, and its melting point is >157 degree Celsius. It has a density of 1.242 g/cm3. It is chemically stable under recommended storage conditions (-20 degree Celsius) and is administered orally as a therapeutic agent. It should be handled with care, as exposure may cause adverse health effects, and prolonged or inappropriate exposure can lead to serious systemic effects.